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Abstract  
Estimates of adherence to antihypertensive treatment in pregnancy are limited; identifying 
non-adherence could facilitate intervention and optimise blood pressure control. This study 
aimed to evaluate adherence to antihypertensive treatment amongst pregnant women with 
chronic hypertension using high-performance liquid chromatography-tandem mass 
spectrometry instrumentation. Spot urine samples collected from women who were 
randomised to labetalol or nifedipine were assessed. Samples from 74 women were 
included; documented prescribing and urine metabolite detection were concordant in 88% 
(n=65). Evidence of self-administration of alternative treatment was observed in 8% (n=6). 
Measurement of urinary antihypertensive metabolites in pregnancy provides insight into 
treatment adherence.  
Key words: Pregnancy, Chronic Hypertension, Adherence, Antihypertensive treatment 
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Introduction  
Non-adherence to medication is considered a key barrier to effective treatment of chronic 
health conditions such as hypertension.(1) The real and perceived risk of fetal harm impacts 
adherence to prescription medication in pregnancy.(2, 3) Prevalence of non-adherence to 
antihypertensive medication in pregnancy is estimated to be between 3% and  65%;(4) the 
wide range of this estimate relates to lack of direct and objective methods of assessing 
adherence. Indirect methods currently used include interviews and questionnaires 
(Morisky’s scale (5) and the Medication Adherence report scale (MARS)(6)), which can be 
subject to recollection bias. Other indirect methods include automated monitoring methods 
such as digitialised records of pharmacy prescription refills or medication event monitoring 
systems but these measures do not allow for patients engaging in pill dumping.(7)  
 
High-performance liquid chromatography-tandem mass spectrometry instrumentation (LC-
MS/MS) represents a novel technique that can be utilized as a direct method for assessing 
adherence to antihypertensive treatment; plasma or urine can be analysed to detect 
metabolites of a wide range of antihypertensive agents.(8) This study aimed to evaluate this 
new technique in assessing adherence amongst pregnant women with chronic hypertension 
randomised to antihypertensive treatment. 
 
Methods 
The cohort consisted of women with chronic hypertension randomised to labetalol or 
nifedipine as first-line antihypertensive treatment within the PANDA study (Pregnancy And 
chronic hypertension: NifeDipine versus lAbetalol as antihypertensive treatment) between 
2014 and 2016. The PANDA study was registered with ISRCTN (DOI 
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10.1186/ISRCTN40973936, www.isrctn.com) and approved by the UK Research Ethics 
Committee (REC number 13/EE/0390). Women were enrolled at three consultant-led 
obstetric units in the UK (Guy’s and St Thomas’ NHS Foundation Trust, Central Manchester 
University NHS Foundation Trust, and University of Leicester Hospitals NHS Trust). The trial 
methodology and findings have previously been published.(9) The women who participated 
in the trial consented to providing urine samples for future research purposes but, as this 
was a post hoc analysis, they were not aware their urine would be tested for 
antihypertensive metabolites at the time of sampling. Results were therefore not fed back 
to the clinician or women. 
 
Urine analysis—LC-MS/MS 
Spot urine samples were collected at routine antenatal clinic appointments following study 
enrollment. The samples were transferred from the clinic to the laboratory at room 
temperature and stored at -80°C until further analysis.  
 
LC-MS/MS was performed using an Agilent Technologies 1290 series High Pressure Liquid 
Chromatograph interfaced with an Agilent Technologies 6460 Triple Quad Mass 
Spectrometer fitted with a Jetstream electrospray (ESI) source. The nebuliser gas 
temperature was set at 350°C with a flow of 5 L/min and a pressure of 45 psi. The sheath 
gas temperature was set at 250°C and a flow of 11 L/min. The LC system was operated in 
gradient mode using 0.1% acetic acid in water for mobile phase A and 0.1% acetic acid in 
methanol for mobile phase B. The initial conditions of 5% B/ 95% A were held for 2 min and 
then ramped to 60% B at 6 min and further 100% B at 9 min. The gradient was held at 100% 
B for 1 min and then returned to 5% B at 11 min to re-equilibrate. The total run time was 12 
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min per sample. An Agilent technologies Zorbax Eclipse Plus C18 2.1×50 mm column was 
used for the LC separation. 
 
The presence or absence of metabolites of labetalol and nifedipine was assessed in two 
samples taken at the same timepoint to ensure concordance of findings. Non-adherence to 
antihypertensive treatment was defined as complete absence of any prescribed 
antihypertensive metabolites in a spot urine sample on screening.  
 
Results 
Urine samples from 74 women (130 samples) randomised to first-line antihypertensive 
treatment were included in the analysis (n=39 randomised to labetalol and n=35 
randomised to nifedipine). Baseline maternal characteristics at enrolment and maternal and 
perinatal outcomes were similar between treatment groups (Table 1). Among the women 
prescribed nifedipine as first-line antihypertensive treatment, 5 (14%) required additional 
treatment with labetalol; no women in the labetalol group were prescribed nifedipine as a 
second-line agent at the time of sampling.  
 
Documented prescribing and urine metabolite detection were concordant in 88% (65/74) of 
women. The proportion of women with metabolite of each antihypertensive detected in 
their urine are provided in Figure 1. In 6 (8%) women, there was evidence of 
antihypertensive metabolite in their urine which differed from what had been prescribed; 
one with nifedipine metabolite only when prescribed labetalol, three with labetalol 
metabolite only when they were prescribed nifedipine, two with nifedipine in addition to 
their prescribed labetalol. 
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Discussion 
To our knowledge, this is the first study to use this novel technique for detection of urinary 
drug metabolites in the direct assessment of adherence with prescribed antihypertensive 
medication in pregnancy. We demonstrate good concordance (88%) of antihypertensive 
agent prescription and detection of urinary drug metabolites in pregnant women with 
chronic hypertension. The need to explore barriers to adherence with women is highlighted, 
with some women only taking one of their prescribed treatments and others taking 
medication that was undocumented.  
 
Outside pregnancy this technique has been used to highlight non-adherence among those 
referred to secondary care with ‘drug-resistant’ hypertension;(8) Tomaszewski and 
colleagues (2014) demonstrated non-adherence in 25% of their secondary care cohort and 
found an association between non-adherence and referral for renal denervation for 
suspected resistant hypertension. Non-adherence within our cohort was lower (12%); this 
may reflect that the women were participating in a randomised controlled trial. Women 
who agree to take part in a research trial may be more likely to adhere to their medication.  
 
Severe hypertension in pregnancy is associated with an increased risk of adverse maternal 
and perinatal outcome.(10) Non-adherence with antihypertensive treatment in pregnancy is 
likely to increase a woman’s risk of severe hypertension and therefore adverse outcome. 
Direct assessment of urinary antihypertensive metabolites provides insight into adherence 
patterns in pregnancy but does not improve understanding of why women may be non-
adherent. Clinicians caring for women with hypertensive disorders in pregnancy need to 
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consider the health beliefs and potential barriers to medication adherence and ensure 
consultations harbour an environment where women are empowered to discuss these 
issues. 
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Figure 1: Overview of study groups and adherence patterns  
Labetalol doses 200 to 1200mg per day and Nifedipine doses 20 to 80mg per day. 
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Table 1: Baseline characteristics and maternal and perinatal outcomes 
 
Overall cohort 
(n=74) 
Randomised to 
Labetalol 
(n=39) 
Randomised to 
Nifedipine 
(n=35) 
Age at study entry*, years  35 (5) 35 (5) 35 (5) 
Body mass index*, kg/m2 31 (6) 31 (7) 31 (5) 
Nulliparous 17 (23%) 9 (23%) 8 (23%) 
Ethnicity 
   
White  21 (28%) 11 (28%) 10 (28%) 
Black  39 (53%) 20 (51%) 19 (54%) 
Asian  10 (14%) 5 (13%) 5 (14%) 
Other  4 (5%) 3 (8%) 1 (3%) 
Booking blood pressure*, mmHg    
Systolic 136 (21) 138 (19) 137 (14) 
Diastolic 87 (16) 88 (15) 87 (11) 
Superimposed pre-eclampsia 12 (16%) 3 (8%) 9 (26%) 
Mode of delivery    
Spontaneous vaginal  27 (36%) 16 (41%) 11 (31%) 
Assisted vaginal 5 (7%) 2 (5%) 3 (9%) 
Elective Caesarean section 11 (15%) 6 (15%) 5 (14%) 
Emergency Caesarean section 31 (42%) 15 (39%) 16 (46%) 
Gestation at delivery*, days 260 (25) 265 (20) 256 (28) 
Preterm birth <37 weeks 18 (24%) 5 (13%) 13 (37%) 
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Livebirth 71 (96%) 38 (97%) 33 (94%) 
Birthweight*, grams 2790 (840) 2900 (720) 2670 (930) 
Birthweight <10th centile 26 (35%) 14 (36%) 12 (34%) 
Neonatal unit admission 14 (19%) 5 (13%) 9 (26%) 
*Mean (SD) 
 
